Clinical Trials

52 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05554380 2026-03-18

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Phase 2 Suspended

33 enrolled

Neoplasm Metastasis

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast Neoplasms

NCT04253561 2026-03-16

IPATHER

17 enrolled

Breast Neoplasms

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

316 enrolled

Neoplasm Metastasis

NCT05862285 2026-03-13

UmbrellaMAX

Phase 3 Recruiting

100 enrolled

Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT04589845 2026-03-06

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 1 Active not recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

25 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

314 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

77 enrolled

Breast Neoplasms

NCT04486352 2025-09-04

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Endometrial Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 1/2 Active not recruiting

200 enrolled

Genitourinary

Prostatic Neoplasms

NCT03072238 2025-06-06

IPATential150

Phase 3 Completed

1,101 enrolled 35 charts

Genitourinary

Prostatic Neoplasms

NCT03673787 2025-05-14

IceCAP

87 enrolled

CNS

Glioblastoma

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT05498896 2025-03-10

BARBICAN

146 enrolled

Triple Negative Breast Neoplasms

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

72 enrolled

Neoplasm Metastasis

NCT04060862 2024-11-08

IPATunity150

Phase 1 Terminated

20 enrolled 11 charts

Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

54 enrolled

Triple Negative Breast Neoplasms

NCT03395899 2024-06-18

ECLIPSE

71 enrolled

Breast Neoplasms

NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3 Completed

242 enrolled 12 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

NCT03337724 2024-03-12

IPATunity130

Phase 3 Completed

579 enrolled 33 charts

Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT04737109 2023-11-13

ADDItion

Phase 1/2 Terminated

6 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT04467801 2023-11-07

Ipat-Lung

Phase 2 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03840200 2023-10-30

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

BreastGenitourinaryGynecologic

51 enrolled 20 charts

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT04920708 2023-10-27

FAIM

324 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04341259 2023-05-08

A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

12 enrolled

Other solid neoplasm

Solid Tumors

NCT01896531 2022-03-02

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

153 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

122 enrolled

Neoplasms

NCT04739202 2021-03-29

IMMUNOGAST

Phase 2 Unknown

60 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04561817 2020-10-06

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2 Withdrawn

Ovarian Neoplasms, Recurrence

NCT02301988 2018-10-17

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

151 enrolled 22 charts

Breast Neoplasms

NCT02536391 2016-11-02

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

18 enrolled

Neoplasms

NCT01090960 2016-07-04

A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors

52 enrolled

Solid Cancers

NCT01562275 2016-03-28

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

67 enrolled 24 charts